<DOC>
	<DOCNO>NCT00826384</DOCNO>
	<brief_summary>According radiology imaging , patient HCC divide two group ( hypovascular tumor group moderately vascular tumor group ) . Every group divide TACE therapy balloon catheter subgroup regular TACE therapy subgroup . Patients take TACE therapy 45 day , MRI diffusion examine CT one week next therapy . All object observed end event happen group 6 month .</brief_summary>
	<brief_title>Transarterial Chemoembolization ( TACE ) Therapy Hepatocellular Carcinoma ( HCC ) With Blocking Tumor Blood Temporarily Enhancing Perfusion</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>sign write informed consent form provide . diagnose clinically HCC , need take TACE . allergic reaction follow iodine . TACE radiotherapy biotherapy within 30 day study . HCC diffuse type , failure hepatic function , chronic illness disease include failure heart function , uncontrolled high blood pressure , heart disorder , serious infection , uncontrolled diabetes mellitus .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>transcatheter arterial chemoembolization</keyword>
	<keyword>overall survival</keyword>
</DOC>